• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Exits

R Capital’s LDR Medical floats on Nasdaq

  • Ellie Pullen
  • 18 October 2013
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

R Capital Management portfolio company LDR Medical raised $75m in an IPO on the Nasdaq, giving the company a market cap of $489m.

LDR's shares began trading on 9 October under the ticker symbol "LDRH". The company sold 5 million shares at a price of $15 per share for its IPO, with an over-allotment option of 750,000 shares at $15 per unit, which the underwriters exercised on 10 October.

LDR initially filed confidentially for the IPO in June this year. Piper Jaffray, William Blair and Bryan Garnier & Co acted as joint bookrunners for the flotation, while Cowen, JMP Securities and Stephens acted as co-managers.

LDR Medical

  • DEAL:

    IPO

  • VALUE:

    $489m (market cap)

  • LOCATION:

    Troyes

  • SECTOR:

    Medical equipment

  • FOUNDED:

    2000

  • TURNOVER:

    $90.9m

  • EBITDA:

    $1.2m

Following the flotation, R Capital – which is part of Rothschild Group – will remain LDR's largest shareholder. Alongside R Capital, LDR is backed by Austin Ventures, PTV Sciences and Telegraph Hill Partners.

Prior to the IPO, R Capital held a 21.1% stake in LDR, while Austin owned 18.3%, via its Austin Ventures VIII fund, Telegraph Hill owned 17.3% and PTV owned 11.3%.

Following the issuance of converted preferred stock to ordinary stock by LDR for its IPO, R Capital now holds a diluted stake of 16.4% while Austin holds 14.3%, Telegraph Hill 13.5% and PTV 8.8%.

LDR plans on using the proceeds from the IPO to finance the production and marketing of its new product, which received approval from the US Food and Drug Administration (FDA) last year. The company also plans on repaying the debt facility that was supplied to the company by Escalate Capital Partners, according to LDR's Securities and Exchange Commission (SEC) S-1 filing.

Company
Founded in 2000, LDR has its European headquarters in Troyes, France, as well as US headquarters in Austin, Texas, and additional offices in Sao Paulo, Seoul and Beijing. The company recorded revenues of $90.9m in 2012, as well as an EBITDA of $1.2m.

LDR designs and develops spinal implant devices, which are designed to make procedures involving spinal surgery easier to perform. The company's recently FDA-approved product, the Mobi-C cervical disc replacement device, is designed to replace artificial discs in the vertebral column for damaged ones, with the aim of maintaining spinal mobility and preventing further degeneration in other vertebral discs.

People
CEO Christophe Lavigne, executive vice president of research and development Hervé Dinville and general manager Patrick Richard are the founders of LDR. Pierre Rémy is a managing partner at R Capital.

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Exits
  • France
  • Healthcare
  • France
  • IPO
  • Rothschild

More on Exits

Public sector software
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • Exits
  • 04 September 2023
Lender taking the keys from a sponsor
Ares Management handed keys to two-thirds of UK sponsor’s portfolio

Lender provided GBP 500m for three of the GP's deals between 2016 and 2019, Debtwire reported

  • Financing
  • 30 August 2023
Luggage and airport services
Actera Group explores strategic options for Celebi Ground Handling

Several investors placed bids for the company in 2022 but mismatch in pricing didn't lead to a deal

  • Exits
  • 30 August 2023
HR software solutions providers
Main Capital’s Assessio to be sold to Pollen Street

Recruitment software company tripled in revenue under Main Capital’s ownership

  • Buyouts
  • 25 August 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013